Features | Partner Sites | Information | LinkXpress
Sign In
Ettin Group
Schiller
GLOBETECH PUBLISHING

Medtronic Buys Tyrx Antibacterial Envelope Manufacturer

By HospiMedica International staff writers
Posted on 13 Jan 2014
Startup company Tyrx (Monmouth Junction, NJ, USA), which manufactures bioresorbable envelopes for implanted medical devices, is now a part of Medtronic (Minneapolis, MN, USA), the world's largest medical device company.

The acquisition supports Medtronic's expansion of its medical device product offerings to include broader healthcare services and solutions, providing meaningful clinical outcomes and economic value for hospitals, physicians, patients, and payers. TYRX brings to Medtronic the AIGISRx R fully resorbable antibacterial envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs), and the AIGISRx N antibacterial envelope, used with spinal cord neurostimulators.

The bioresorbable envelopes use a combination of two antibiotic drugs: Minocycline and Rifampin. Minocycline is a tetracycline-class antibiotic commonly used to treat skin acne, among other things; Rifampin is commonly used to treat tuberculosis. Both drugs have different modes of action, and working together target roughly 80% of the germs, which can be introduced during surgery, including Methicillin Resistant Staphylococcus aureus (MRSA) and a number of other pathogens.

“While the risk of infection from an implanted pacemaker or defibrillator is low for most patients, repeated operative procedures after the initial device implant are associated with a substantial incremental risk of infection. This is estimated to cost the US healthcare system more than one billion dollars per year,” said Pat Mackin, president of the cardiac rhythm disease management business and senior vice president at Medtronic. “TYRX has developed an innovative, proven technology to reduce infection risk, making the procedure safer for patients and removing significant costs from the healthcare system.”

“We look forward to joining Medtronic as part of a combined portfolio that can positively impact outcomes for patients by reducing implant-related infections, and bring value to our customers,” said Robert White, president and CEO of Tyrx.

The all-cash transaction includes an initial payment of USD 160 million plus potential earn out and performance based milestone payments.

Related Links:

Tyrx
Medtronic
Antibacterial Envelope Protects Cardiac Implants




ECR
ACEM
Cincinnati Sub-Zero

Channels

Critical Care

view channel

Bee Bacteria Could Provide Alternative to Antibiotics

A new study demonstrates that a unique lactic acid bacteria (LAB) microbiota in the honey stomach of bees can counteract antibiotic-resistant microbes. Researchers at Lund University (Sweden) have discovered 13 LAB that live in symbiosis with honeybees, and are present in large amounts in fresh honey across the world.... Read more

Surgical Techniques

view channel
Image: The NICO BrainPath surgical obturators and sheaths (Photo courtesy of NICO).

Brain Access Sheath Safely Displace Subcortical Tissue

A novel access device minimizes neural damage by gently displacing tissues during advancement towards hard-to-reach brain abnormalities. The BrainPath device provides surgical access to brain abnormalities... Read more

Women's Health

view channel

Aspirin Reduces Breast Cancer Recurrence in Overweight Women

The recurrence of hormone-related breast cancer was reduced by more than half in overweight and obese women who regularly used nonsteroidal anti-inflammatory drugs (NSAIDs), according to a new study. Researchers at the University of Texas (UT; Austin, USA) conducted a retrospective review of data from 440 women with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.